サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1375981

特発性血小板減少性紫斑病治療薬の市場規模、シェア、動向分析レポート：疾患タイプ別、地域別、セグメント予測、2023年～2030年

Idiopathic Thrombocytopenic Purpura Therapeutics Market Size, Share & Trends Analysis Report By Disease Type (Corticosteroids, IVIG, Anti-D Immunoglobulins, TPO-RA, Others), By Region, And Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 60 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
特発性血小板減少性紫斑病治療薬の市場規模、シェア、動向分析レポート：疾患タイプ別、地域別、セグメント予測、2023年～2030年
出版日: 2023年10月19日
発行: Grand View Research
ページ情報: 英文 60 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

特発性血小板減少性紫斑病治療薬市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、特発性血小板減少性紫斑病治療薬の世界市場は、2023年から2030年にかけてCAGR 5.0%で拡大し、2030年までに9億1,490万米ドルに達する見込みです。

IVIGやTPO-RAクラスの新薬導入につながる研究開発の増加が、予測期間中の成長を促進すると予想されます。さらに、新製品開発を奨励することを目的とした米国の希少疾病用医薬品法（Orphan Drug Act）のような政府規制が成長を促進すると予測されています。

併用療法は他の治療法に比べて高い効率を示すため、業界では併用療法への需要が高まっています。さらに、費用効率が高く、個々の治療クラスに関連する副作用を抑制するのに役立ちます。主な併用療法には、デキサメタゾンとリツキシマブ、デキサメタゾンとTPO-RA、IVIG、コルチコステロイドなどがあります。脾臓摘出術（脾臓を摘出する手術）は、抗血小板抗体の量を減少させることを目的としており、需要に拍車がかかると予想されます。副腎皮質ステロイドは特発性血小板減少性紫斑病の治療に定期的に使用されています。副腎皮質ステロイドはITP患者の治療の第一選択薬と考えられているため、副腎皮質ステロイドの使用率は非常に高いです。

特発性血小板減少性紫斑病治療薬市場レポート・ハイライト

  • TPO-RAは、エルトロンボパグとロミプロスチムを投与された患者の奏効率が高いことから、2023年から2030年にかけてCAGR 6.6%以上で成長し、大幅な成長が見込まれます。さらに、2015年にアバトロンボパグが商業化されたことにより、TPO-RAの需要が増加すると予想されます。加えて、TPO-RAは脾臓摘出患者の再発に対応できることから、今後6年間の需要に拍車がかかると予想されます。
  • 北米が市場を独占し、2022年には39.9%の最大売上シェアを占めました。
  • アジア太平洋地域は予測期間中最も速いCAGR 6.2％で成長すると予想されます。
  • アジア太平洋地域は、オーストラリアと日本における政府の積極的な取り組みと洗練されたヘルスケアインフラの存在により、今後6年間で大幅な成長が見込まれています。さらに、中国やインドなどの新興市場には未開拓の機会が多く存在するため、成長が促進されると予想されます。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 特発性血小板減少性紫斑病治療薬市場の変数、動向および範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 普及と成長の見通しマッピング
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 特発性血小板減少性紫斑病治療薬市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 特発性血小板減少性紫斑病治療薬市場：疾患タイプの推定・動向分析

  • 特発性血小板減少性紫斑病治療薬市場、疾患タイプ別の重要なポイント
  • 特発性血小板減少性紫斑病治療薬市場：動向と市場シェア分析、2022年および2030年
  • 急性ITP
  • 慢性
  • その他

第5章 特発性血小板減少性紫斑病治療薬市場：製品の推定・動向分析

  • 特発性血小板減少性紫斑病治療薬市場、製品別の重要なポイント
  • 特発性血小板減少性紫斑病治療薬市場：動向と市場シェア分析、2022年および2030年
  • コルチコステロイド
  • IVIG
  • 抗D免疫グロブリン
  • TPO-RA
  • その他

第6章 特発性血小板減少性紫斑病治療薬市場：地域推定・動向分析

  • 地域別の展望
  • 地域別の特発性血小板減少性紫斑病治療薬市場：主要マーケットプレースのポイント
  • 北米
    • 市場推計・予測、2018～2030年
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • スウェーデン
    • ノルウェー
    • デンマーク
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • タイ
    • 韓国
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 会社/競合の分類
    • Amgen Inc.
    • F. Hoffmann-La Roche Ltd
    • Grifols, S.A.
    • GSK plc.
    • Shangxian Minimal Invassive Inc.
    • INTROMEDIC
    • Medtronic
    • FUJIFILM Holdings Corporation
    • Olympus Corporation
    • JINSHAN Science & Technology (Group) Co., Ltd.
図表

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 3 North America idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 4 North America idiopathic thrombocytopenic purpura therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 5 U.S. idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 6 U.S. idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 7 Canada idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 8 Canada idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 9 Europe idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 10 Europe idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 11 Europe idiopathic thrombocytopenic purpura therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 12 Germany idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 13 Germany idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 14 UK idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 15 UK idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 16 France idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 17 France idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 18 Italy idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 19 Italy idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 20 Spain idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 21 Spain idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 22 Denmark idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 23 Denmark idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 24 Sweden idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 25 Sweden idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 26 Norway idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 27 Norway idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific idiopathic thrombocytopenic purpura therapeutics market, by country, (USD Million) 2018 - 2030
  • Table 31 Japan idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 32 Japan idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 33 China idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 34 China idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 35 India idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 36 India idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 37 Thailand idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 38 Thailand idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 39 South Korea idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 40 South Korea idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 41 Latin America idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 42 Latin America idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 43 Latin America idiopathic thrombocytopenic purpura therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 44 Brazil idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 45 Brazil idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 46 Mexico idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 47 Mexico idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 48 Argentina idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 49 Argentina idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 50 Middle East and Africa idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 51 Middle East and Africa idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 52 Middle East and Africa idiopathic thrombocytopenic purpura therapeutics market, by country, (USD Million) 2018 - 2030
  • Table 53 Saudi Arabia idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 54 Saudi Arabia idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 55 South Africa idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 56 South Africa idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 57 UAE idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 58 UAE idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 59 Kuwait idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 60 Kuwait idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Idiopathic thrombocytopenic purpura therapeutics: market outlook
  • Fig. 9 Idiopathic thrombocytopenic purpura therapeutics competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Idiopathic thrombocytopenic purpura therapeutics market driver impact
  • Fig. 15 Idiopathic thrombocytopenic purpura therapeutics market restraint impact
  • Fig. 16 Idiopathic thrombocytopenic purpura therapeutics market strategic initiatives analysis
  • Fig. 17 Idiopathic thrombocytopenic purpura therapeutics market: Disease type movement analysis
  • Fig. 18 Idiopathic thrombocytopenic purpura therapeutics market: Disease type outlook and key takeaways
  • Fig. 19 Acute ITP market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Chronic market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Idiopathic thrombocytopenic purpura therapeutics market: Product type movement analysis
  • Fig. 23 Idiopathic thrombocytopenic purpura therapeutics market: Product type outlook and key takeaways
  • Fig. 24 OGIB market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 IVIG market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Anti-D immunoglobulins market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 TPO-RA market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Global idiopathic thrombocytopenic purpura therapeutics market: Regional movement analysis
  • Fig. 30 Global idiopathic thrombocytopenic purpura therapeutics market: Regional outlook and key takeaways
  • Fig. 31 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
目次
Product Code: 978-1-68038-289-1

Idiopathic Thrombocytopenic Purpura Therapeutics Market Growth & Trends:

The global idiopathic thrombocytopenic purpura therapeutics market is expected to reach USD 914.9 million by 2030, expanding at a CAGR of 5.0% from 2023 to 2030, according to a new report by Grand View Research, Inc.. Rising R&D leading to the introduction of new drugs for IVIG and TPO-RA classes is expected to propel growth over the forecast period. In addition, government regulation such as the Orphan Drug Act in the United States with an aim to encourage new product development is projected to fuel growth.

The industry is characterized by a rising demand for combination therapies as they exhibit higher efficiency as compared to other treatments. Moreover, they are cost-efficient and help curb side effects associated with individual therapeutic classes. Some of the major combination therapies are dexamethasone and rituximab, dexamethasone and TPO-RA, IVIG, and corticosteroids. Splenectomy, the procedure to remove the spleen is aimed at reducing the amount of anti-platelet antibodies, is expected to fuel demand. Corticosteroids are regularly used in idiopathic thrombocytopenic purpura treatment. Since corticosteroid are considered to be the first line of therapy for patients suffering from ITP, the usage rates of corticosteroid are very high.

Idiopathic Thrombocytopenic Purpura Therapeutics Market Report Highlights:

  • TPO-RA is likely to witness substantial growth, growing at a CAGR of over 6.6% from 2023 to 2030 owing to high response rates exhibited by patients administered with Eltrombopag and Romiplostim. Moreover, demand for TPO-RA is expected to increase due to the commercialization of Avatrombopag in 2015. In addition, the ability of TPO-RA to cater to splenectomized patients witnessing relapses is expected fuel demand over the next six years.
  • North America dominated the market and accounted for the largest revenue share of 39.9% in 2022.
  • Asia Pacific is expected to grow at the fastest CAGR of 6.2% over the forecast period.
  • Asia Pacific is expected to experience substantial growth over the next six years, owing to the presence of favorable government initiatives, and sophisticated healthcare infrastructure in Australia and Japan. In addition, the presence of vast untapped opportunities in emerging markets such as China and India is expected to propel growth.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Disease Type
    • 1.1.2. Product
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1
    • 1.9.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Disease type outlook
    • 2.2.2. Product outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Idiopathic Thrombocytopenic Purpura Therapeutics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Idiopathic Thrombocytopenic Purpura Therapeutics Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Idiopathic Thrombocytopenic Purpura Therapeutics Market: Disease Type Estimates & Trend Analysis

  • 4.1. Idiopathic Thrombocytopenic Purpura Therapeutics Market, By Disease Type Key Takeaways
  • 4.2. Idiopathic Thrombocytopenic Purpura Therapeutics Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Acute ITP
    • 4.3.1. Acute ITP market estimates and forecasts, 2018 to 2030, (USD Million)
  • 4.4. Chronic
    • 4.4.1. Chronic market estimates and forecasts, 2018 to 2030, (USD Million)
  • 4.5. Others
    • 4.5.1. Others market estimates and forecasts, 2018 to 2030, (USD Million)

Chapter 5. Idiopathic Thrombocytopenic Purpura Therapeutics Market: Product Estimates & Trend Analysis

  • 5.1. Idiopathic Thrombocytopenic Purpura Therapeutics Market, By Product Key Takeaways
  • 5.2. Idiopathic Thrombocytopenic Purpura Therapeutics Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Corticosteroids
    • 5.3.1. Corticosteroids market estimates and forecasts, 2018 to 2030, (USD Million)
  • 5.4. IVIG
    • 5.4.1. IVIG market estimates and forecasts, 2018 to 2030, (USD Million)
  • 5.5. Anti-D Immunoglobulins
    • 5.5.1. Anti-D Immunoglobulins market estimates and forecasts, 2018 to 2030, (USD Million)
  • 5.6. TPO-RA
    • 5.6.1. TPO-RA market estimates and forecasts, 2018 to 2030, (USD Million)
  • 5.7. Others
    • 5.7.1. Others market estimates and forecasts, 2018 to 2030, (USD Million)

Chapter 6. Idiopathic Thrombocytopenic Purpura Therapeutics Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Outlook
  • 6.2. Idiopathic Thrombocytopenic Purpura Therapeutics Market by Region: Key Marketplace Takeaway
  • 6.3. North America
    • 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4. Europe
    • 6.4.1. U.K.
      • 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.3. France
      • 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.6. Sweden
      • 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.7. Norway
      • 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.2. China
      • 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.3. India
      • 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.5. Thailand
      • 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.6. South Korea
      • 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.2. Mexico
      • 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7. MEA
    • 6.7.1. Saudi Arabia
      • 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.2. South Africa
      • 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
    • 7.2.1. Amgen Inc.
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Disease Type benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. F. Hoffmann-La Roche Ltd
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Disease Type benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Grifols, S.A.
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Disease Type benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. GSK plc.
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Disease Type benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. Shangxian Minimal Invassive Inc.
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Disease Type benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. INTROMEDIC
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Disease Type benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Medtronic
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Disease Type benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. FUJIFILM Holdings Corporation
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Disease Type benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. Olympus Corporation
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Disease Type benchmarking
      • 7.2.9.4. Strategic initiatives
    • 7.2.10. JINSHAN Science & Technology (Group) Co., Ltd.
      • 7.2.10.1. Company overview
      • 7.2.10.2. Financial performance
      • 7.2.10.3. Disease Type benchmarking
      • 7.2.10.4. Strategic initiatives